NCE-1 Intelligence & Market Opportunity

Xenpozyme

Olipudase Alfa

Antimetabolic disorder

Injection Injectable

Approval Date

31-Aug-22

NCE-1 Date

31-Aug-26

NCE Date

31-Aug-27

Commercial snapshot

Market performance & projections

Revenue ($M)

257

CAGR (%)

0.1259

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

300

2027

348

2028

385

2029

413

2030

433

2031

449

2032

465

Molecule profile

Details & specifications

Molecule

Olipudase Alfa

Innovator

GENZYME CORPORATION

Dosage Form

Injection Injectable

Strength

20 mg

Therapeutic Category

Antimetabolic disorder

Usage

To treat Acid Sphingomyelinase Deficiency

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.